• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·GTHP
Share

Guided Therapeutics, Inc. Stocks

$ 0.16Last Updated 19.10.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 15.45M

$ 0.16
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guided Therapeutics, Inc. is a medical technology firm specializing in the creation of medical devices. Its primary focus is on bringing to market LuViva, an innovative device designed for the non-invasive detection of cervical cancer. This technology excels at identifying both cancerous and precancerous conditions of the cervix in a painless, non-invasive manner, directly at the point of care. LuViva operates by scanning the cervix with light and subsequently analyzing both the reflected and fluorescent light emitted. Established in 1992 and headquartered in Norcross, Georgia, the company was formerly known as SpectRx, Inc. until its rebranding to Guided Therapeutics, Inc. in February 2008.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 09:00

A Forgotten Sector with AI Potential: How the Citrini Experiment Became an Investment Opportunity

21.10.2026 08:00

JPMorgan has issued its first long-term forecast for Bitcoin. It could outperform stocks and gold

21.10.2026 07:00

Boeing has secured approval for the largest aircraft in the 737 Max family. Why is this important?

21.10.2026 04:37

AI stocks surged: one of the largest server suppliers eased market concerns

21.10.2026 03:02

SpaceX and Tesla Are Discussing a Merger — Musk

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026